Harvard Apparatus Regenerative Technology, Inc.

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company that develops regenerative medicine treatments for disorders of the gastro-intestinal tract and airways. It also operates a consumer health products business in Hong Kong that sells dietary supplements online to consumers in Asia.

−981,5 %

8,2 %

−975,7 %

+63,7 %

1.19

1.18

— Harvard Apparatus Regenerative Technology, Inc.
%
Regenerative medicine therapies0% Development-stage therapies intended to restore organ function in the GI tract and airways.
Synthetic scaffolds and preclinical programs0% Research programs focused on scaffold materials, cellularization, and preclinical validation.
Consumer health products100% Dietary supplements and personal healthcare products sold through the Hong Kong subsidiary.

The core biotechnology business is aimed at patients with cancers, injuries, or birth defects affecting the...

  • Patients with GI and airway disordersprimary

    Future end users of regenerative therapies intended to restore organ function after cancer, trauma, or birth defects.

  • General consumers in Asiaprimary

    Buy dietary supplements and consumer health products through online channels from the Hong Kong subsidiary.

  • Clinical investigators and trial sitessecondary

    Support the company’s development programs by enrolling patients and generating clinical evidence.

  • Healthcare providerssecondary

    Potential future prescribers or adopters of approved regenerative therapies.

The company is headquartered in the United States but its commercial consumer health activity is targeted at Asia...

  • •United States is the corporate base and a potential approval pathway
  • •Hong Kong subsidiary anchors the consumer health business
  • •Asia is the current market for online supplement sales
  • •China is a strategic regulatory and commercialization option
  • •Geography matters because approvals, capital access, and partnerships differ by market

The company is trying to advance regenerative medicine programs while preserving optionality on where the first...

01
Clinical development and regulatory pathway selectionshort-term

The company needs a viable approval route before its implant products can become commercial.

02
Capital raising and liquidity preservationshort-term

The business is cash constrained and needs external funding to continue operations.

03
Build consumer health revenuemedium-term

Supplement sales provide a commercial revenue stream while biotech programs remain unapproved.

The company faces substantial going-concern and financing risk because it has limited cash, ongoing operating losses,...

critical

Liquidity and going-concern risk

The company expects continued operating losses and needs additional capital to fund operations.

Scope
Core biotech operations and corporate continuity
Materiality
high
high

Regulatory approval risk

Product candidates are not approved anywhere and commercialization depends on successful clearance.

Scope
Regenerative medicine pipeline
Materiality
high
high

Clinical recruitment and trial execution risk

Management notes recruitment challenges and the need to increase trial sites and outreach.

Scope
Clinical-stage development programs
Materiality
high
medium

China market and partnership risk

A China pathway may involve a joint venture, licensing terms, and local regulatory uncertainty.

Scope
Potential commercialization and financing strategy
Materiality
medium
medium

Consumer health competition risk

Online supplement sales depend on consumer demand, marketing efficiency, and platform visibility.

Scope
Asia eCommerce supplement business
Materiality
medium
Research and development expense recognition
Higher trial activity increases operating loss
Share-based compensation
Can materially affect operating loss and dilution analysis
Convertible debt and financing costs
Affects net loss and financing burden
Going-concern disclosure
Important for liquidity assessment and valuation

HARVARD BIOSCIENCE INC

HBIO · Laboratory Analytical Instruments

BioRestorative Therapies, Inc.

BRTX · Services-Misc Health & Allied Services, NEC

Celularity Inc

CELU · Pharmaceutical Preparations

Regenerative Medical Technology Group Inc.

RMTG · Retail-Retail Stores, NEC

International Stem Cell CORP

ISCO · Pharmaceutical Preparations

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

: 28/04/2026